Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin DE000BAY0017
Ticker BAYN.DE
Company BAYER
Currency
Price
Aware Investor Index (AII) 0.8845
Recommendation BUY
P/E 23.91
ROE 11.92 %
Capitalization 62,470,056,170 $
Dividend Yield 4.54 %
P/S 1.54
AII Position 269
P/E Position 330
ROE Position 306
Capitalization Position 151
Dividend Yield Position 98
Sales 35,015,000,000 €
10-Year Average Earnings 2,250,400,000 €
Shares Outstanding 872,107,808
Equity 18,875,000,000 €
Dividend per Share 2.8 €
Industry Pharmaceutical
Country Germany
BAYER Investor Relations Web Site http://www.investor.bayer.com/en/







Sales:

YEAR MONTH AMOUNT
2017 12 35,015,000,000.00 €
2016 12 34,943,000,000.00 €
2015 12 46,324,000,000.00 €
2014 12 42,239,000,000.00 €
2013 12 40,157,000,000.00 €
2012 12 39,760,000,000.00 €
2011 12 36,528,000,000.00 €
2010 12 35,088,000,000.00 €
2009 12 31,168,000,000.00 €
2008 12 32,918,000,000.00 €

Earnings:

YEAR MONTH AMOUNT
2017 12 2,900,000,000.00 €
2016 12 2,233,000,000.00 €
2015 12 4,110,000,000.00 €
2014 12 3,426,000,000.00 €
2013 12 3,189,000,000.00 €
2012 12 889,000,000.00 €
2011 12 1,125,000,000.00 €
2010 12 1,245,000,000.00 €
2009 12 2,226,000,000.00 €
2008 12 1,161,000,000.00 €

Equity:

YEAR MONTH AMOUNT
2017 12 18,875,000,000.00 €
2016 12 16,565,000,000.00 €
2015 12 24,265,000,000.00 €
2014 12 20,106,000,000.00 €
2013 12 13,888,000,000.00 €
2012 12 14,363,000,000.00 €
2011 12 13,888,000,000.00 €

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 872,107,808
2016 12 832,502,808
2015 12 826,947,808
2014 12 826,947,808
2013 12 826,947,808
2012 12 826,947,808
2011 12 826,950,000

 












Bloomberg News for BAYER:



Google News for BAYER:

The Clayton Caller - 5 hours ago
Trading Monitor: Bayer AG (BAYN.DE) Stock Topping Chikou Line
At current levels, Bayer AG (BAYN.DE) is trading on top of the Chikou. If the stock continues to stay above the line, traders might be anticipating ...
The Pharma Letter - 5 Apr 2019
Bayer defeats malicious cyber attack
German pharma major Bayer (BAYN: DE) says it has neutralized a cyber threat present on its network for more than a year. The firm reportedly ...
The Pharma Letter - 25 Mar 2019
Bayer and Janssen settle Xarelto litigation
More than five years after the blood thinner Xarelto (rivaroxaban) litigation began, and with Germany's Bayer (BAYN: DE) and Johnson ...
The Pharma Letter - 21 Mar 2019
Bayer turns digital health programs into joint initiative
German life sciences group Bayer (BAYN: DE) has combined its digital health programs to form the G4 Partnerships initiative. Instead of one-off ...
The Pharma Letter - 3 days ago
Novartis looks to favorable dosing regimen for edge in wet AMD
The product, which is joint-marketed with Germany's Bayer (BAYN: DE), is approved for intravitreal injection every four or every eight weeks, ...
FXStreet - 25 Mar 2019
German IFO beats expectations; focus on UK Cabinet meeting on ...
Healthcare: Bayer [BAYN.DE] -2.5% (analyst action), PharmaMar [PHM.ES] +3% (study met primary endpoint). - Industrials: Fiat Chrysler [FCA.
The Pharma Letter - 9 Apr 2019
XOMA invests in five Aronora candidates
Of the assets, three are antithrombotic candidates that are covered by a collaboration with German pharma major Bayer (BAYN: DE), two of ...
FXStreet - 28 Mar 2019
Euro Area inflation continues to be soft
Healthcare: Bayer [BAYN.DE] -1.5% (statement on Jury's decision), Evotec [EVT.DE] +4% (earnings). - Industrials: Manz Automation [M5Z.
The Pharma Letter - 22 Mar 2019
Study finds Nexavar can be repurposed beyond known uses
The drug identified, sorafenib, marketed by Germany's Bayer (BAYN: DE) as Nexavar, is widely used for the treatment of kidney and liver ...
The Pharma Letter - 10 Apr 2019
LEO continues busy period of dealmaking with new drug delivery ...
LEO has been actively seeking to bolster its pipeline, with the acquisition of Bayer's (BAYN: DE) dermatology unit in July 2018, as well as deals ...


Back